Copyright © 2001 by the European Society of Cardiology.
Letter to the Editors
Letter to the Editor: Clinical implications of clinical studies: can we compare different subgroups defined a posteriori?
Instituto di Ricerche Farmacologiche Mario Negri Sud, Angela Valenti Laboratory of Genetic and Environmental Risk Factors for Thrombotic Diseases, Department of Vascular Medicine and Pharmacology, S.Maria Imbaro, Italy
References
- Rubins HB, Collins D, Robins SJ. The VA HDL Intervention Trial: clinical implications. Eur Heart J. 2000;21:11131115
[Free Full Text] - Rubins HB, Robins SJ, Collins D. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410418
[Abstract/Free Full Text] - Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:10011009
[Abstract/Free Full Text] - N Engl J Med. 1998;339:13491357
[Abstract/Free Full Text]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||